Sickle Cell Gene Therapy 'Truly Transformative'

Patients who received lovo-cel had durable remissions and reductions in vaso-occlusive events, pain crises, and hospitalizations in the longest running gene therapy trial for sickle cell disease.

Related Keywords

Columbus ,Ohio ,United States ,Ann Arbor ,Michigan ,American ,Sarah Obrien ,Julie Kanter ,University Of Michigan School Medicine ,University Of Alabama ,American Society Of Hematology ,Vertex Pharmaceuticals ,Drug Administration ,American Society ,Saraho Brien ,Nationwide Children ,Crispr Therapeutics ,Steven Pipe ,Michigan School ,Genomics Genomic Medicine ,Sickle Cell Disease ,Ickle Cell Anemia Sickle Anaemia ,Gene Therapy ,Biologic Therapy ,Iologics ,I Cell Disease ,Ucolipidosis Type Ii ,Nclusion Cell Disease ,Ucolipidosis Ii ,Ol Ii ,Lysosomal Storage Disease ,Pain Management ,Spain ,Hospitals ,Adolescent Medicine ,Teens ,Eenage ,Teenager ,Adolescent Health ,Adolescents ,Adolescent ,Blood ,Gene Editing ,